Quick Answer
Skye Bioscience, Inc. reported Operating Income of -$58.16 million for fiscal year 2025.
Skye Bioscience, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$58.16M | -92.6% |
| 2024 | -$30.19M | +13.1% |
| 2023 | -$34.74M | -89.7% |
| 2022 | -$18.31M | -133.3% |
| 2021 | -$7.85M | -24.8% |
| 2020 | -$6.29M | +5.2% |
| 2019 | -$6.63M | -41.3% |
| 2018 | -$4.69M | -21.6% |
| 2017 | -$3.86M | +13.7% |
| 2016 | -$4.47M | -3.6% |
| 2015 | -$4.32M | -58.0% |
| 2014 | -$2.73M | -2168.8% |
| 2013 | -$120.4K | -1562.6% |
| 2013 | -$7.2K | -275.9% |
| 2012 | $4.1K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$13.26M | -167.0% | +27.3% |
| June 30, 2025 | -$18.24M | -117.0% | -55.1% |
| March 31, 2025 | -$11.76M | -91.1% | -136.7% |
| September 30, 2024 | -$4.97M | +79.9% | +40.9% |
| June 30, 2024 | -$8.41M | -195.7% | -36.6% |
| March 31, 2024 | -$6.15M | -98.4% | +75.1% |
| September 30, 2023 | -$24.71M | -745.4% | -769.0% |
| June 30, 2023 | -$2.84M | +11.7% | +8.3% |
- Skye Bioscience, Inc. showed a decrease of -92.6% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Skye Bioscience, Inc.’s operating income has declined by 1412865.7% (from $4.1 thousand to -$58.16 million).
- The most recent figure is from Skye Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: